Claritev (NYSE:CTEV – Get Free Report) major shareholder Ares Management Llc acquired 65,579 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was purchased at an average price of $26.14 per share, with a total value of $1,714,235.06. Following the transaction, the insider owned 2,049,518 shares of the company’s stock, valued at approximately $53,574,400.52. This trade represents a 3.31% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Ares Management Llc also recently made the following trade(s):
- On Monday, November 9th, Ares Management Llc bought 50,000 shares of Claritev stock. The shares were purchased at an average cost of $24.42 per share, for a total transaction of $1,221,000.00.
- On Monday, October 26th, Ares Management Llc bought 20,834 shares of Claritev stock. The shares were acquired at an average price of $24.07 per share, for a total transaction of $501,474.38.
- On Friday, October 23rd, Ares Management Llc bought 50,000 shares of Claritev stock. The shares were acquired at an average price of $23.53 per share, for a total transaction of $1,176,500.00.
Claritev Stock Down 3.9%
Shares of Claritev stock opened at $27.11 on Friday. Claritev has a twelve month low of $11.50 and a twelve month high of $55.50. The business has a 50-day moving average price of $26.42 and a 200 day moving average price of $25.46. The firm has a market cap of $459.51 million, a PE ratio of -1.65 and a beta of 1.05.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on CTEV. Canaccord Genuity Group upped their target price on Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Zacks Research raised shares of Claritev from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Wells Fargo & Company lifted their price target on shares of Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Citigroup reissued a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Finally, Piper Sandler restated an “overweight” rating and set a $73.00 price objective on shares of Claritev in a research report on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.
Get Our Latest Research Report on Claritev
Institutional Investors Weigh In On Claritev
Institutional investors have recently bought and sold shares of the company. Public Investment Fund purchased a new stake in Claritev during the 2nd quarter worth approximately $43,703,438. RBF Capital LLC lifted its position in shares of Claritev by 0.8% in the first quarter. RBF Capital LLC now owns 135,314 shares of the company’s stock valued at $2,211,000 after acquiring an additional 1,127 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Claritev by 146.6% in the first quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock valued at $1,598,000 after acquiring an additional 58,133 shares in the last quarter. FAS Wealth Partners Inc. lifted its position in shares of Claritev by 49.5% in the first quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company’s stock valued at $759,000 after acquiring an additional 15,380 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Claritev by 2.5% in the first quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock valued at $296,000 after acquiring an additional 447 shares in the last quarter. 87.15% of the stock is currently owned by institutional investors and hedge funds.
Claritev Company Profile
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Recommended Stories
- Five stocks we like better than Claritev
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
